Background and Aims: Non-response, loss of response, or intolerance to anti-tumour necrosis factor alpha (anti-TNFα) therapy is well recognised in Crohn's disease (CD) patients. Data concerning outcomes following the use of a second anti-TNFα therapy, particularly in patients who do not respond to a first anti-TNFα agent, are still emerging. The aim of this study was to assess response and tolerability to adalimumab following infliximab failure in a single centre cohort of CD patients. Methods: Data were collected prospectively on 44 patients who received adalimumab therapy following infliximab failure. Initial response to adalimumab therapy at 6 weeks following induction was defined using a two point decrease in the Harvey-Bradshaw Index, with remission at this point defined using a Harvey Bradshaw index ≤ 4. Sustained clinical benefit at the last point of follow up was determined using a physician's global assessment. Corticosteroid-free sustained clinical benefit was also assessed at this point. Results: Thirty-four (77%) patients had initial response to adalimumab therapy, with 28 (64%) having sustained clinical benefit. Corticosteroid-free sustained clinical benefit was achieved in nine (53%) of 17 patients requiring steroids at commencement of adalimumab. Four (44%) of the 9 patients who were primary non-responders to infliximab responded to adalimumab. The majority of CD patients who failed adalimumab therapy required surgery. Conclusions: Second-line anti-TNFα therapy with adalimumab is effective at both inducing remission and maintaining response in CD patients who have failed infliximab, regardless of the reason for infliximab failure.
Introduction
Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract, potentially manifesting at any site from mouth to anus, but most commonly occurring in the terminal ileum and colon. 1 The disease may be complicated by abscess and fistulae formation, perianal disease, and extra-intestinal manifestations including joint, skin, and eye disease. Approximately 80% of patients will require surgery within 10 years of their initial diagnosis. 2 Active CD is associated with excessive levels of pro-inflammatory cytokines in the blood, including tumour necrosis factor alpha (TNFα). 3, 4 Both adalimumab (Humira®, Abbott Laboratories, Illinois, USA) and infliximab (Remicade®, Centocor Ortho Biotech Inc, Pennsylvania, USA) are monoclonal antibodies directed against TNFα. Infliximab is a chimeric antibody, composed of a murine fragment antigen-binding variable region, with the remainder of the antibody being human. Adalimumab is a fully humanised immunoglobulin G1 antibody. Both drugs have been demonstrated to be effective in inducing and maintaining remission in CD, [5] [6] [7] [8] [9] and in reducing the number of CDrelated hospitalisations and surgical interventions, 10, 11 and both are licenced for use in CD.
There are some individuals who do not respond to the standard three dose induction with infliximab, defined as primary nonresponse to therapy. In addition, self-generated antibodies to infliximab (ATI) have been demonstrated in the serum of patients receiving infliximab. 12 These are associated with a secondary loss of response to therapy that is not recaptured by attempts to optimise therapy, which may include a repeat attempt at three dose induction, dose escalation, or reduction of the interval between infusions. 13, 14 Finally, there are some patients who have to discontinue infliximab therapy due to intolerable adverse events. 6, 14 Switching biological therapies in this situation to try to achieve, or regain, response is one potential treatment strategy. The GAIN study is the largest randomised controlled trial (RCT), to date, that has examined the efficacy of switching from infliximab to adalimumab, but excluded those with primary non-response to infliximab. 15 The investigators reported a statistically significant increase in the initial response rates to adalimumab, compared with placebo, but follow-up was only at 4 weeks. Data from routine clinical practise are therefore required regarding the efficacy and safety of switching biological therapies, particularly in the longer term.
We present data from the largest reported cohort of individuals treated in a single UK centre, to date, and report the efficacy, tolerability, and safety of switching from infliximab to adalimumab in CD patients who have failed infliximab therapy due to either primary or secondary non-response, or who have discontinued therapy due to intolerable adverse events.
Materials and methods

Participants and setting
The Inflammatory Bowel Diseases (IBD) Clinic at the Leeds General Infirmary, Leeds, UK has been treating CD patients who have failed infliximab therapy with adalimumab since 2007. This is a large teaching hospital in a city in the North of England, with a population of approximately 800,000, which also receives tertiary referrals from other centres. Once patients are initiated on treatment they are monitored at regular intervals during therapy, by a team of specialist nurses.
Patients included in the present study received one of two induction regimens: adalimumab 160 mg at baseline followed by 80 mg at 2 weeks, then 40 mg every other week (EOW); or adalimumab 80 mg at baseline followed by adalimumab 40 mg EOW. An induction regimen of 80 mg at baseline, followed by 40 mg EOW is currently licenced, but subsequent published data have suggested that patients are less likely to require a reduction in the interval between adalimumab injections to 1 week if they receive an induction dose of 160 mg at baseline, followed by 80 mg at 2 weeks, and subsequently 40 mg EOW, 16 which explains the change to a 160 mg/80 mg induction regimen at our centre.
During the initial induction phase, where patients received the first four treatments of adalimumab over a 6 week period, the drug was administered by an IBD nurse specialist at the Leeds Immune Mediated Inflammatory Diseases Unit. At this time point the patients were assessed for suitability to self-administer adalimumab by the IBD nurse, in order to allow further therapy to be given by the patient in their own home. Patients who received adalimumab as first-line anti-TNFα therapy were not included in this study.
Data collection
Demographic data were collected prospectively for all patients including: sex, smoking status, disease location (including presence or absence of fistulae), age at diagnosis of CD, and a history of major CD-related abdominal surgery. We also collected data concerning previous infliximab regimen used (scheduled or episodic) and duration of therapy, duration of disease prior to commencement of infliximab therapy, and the reason for discontinuation: primary non-response (no response to three dose induction), secondary nonresponse (relapse of disease activity following successful induction therapy), or intolerable adverse events. On commencement of adalimumab therapy, data were collected prospectively concerning the induction regimen used, Harvey Bradshaw Indices (HBI), baseline and post-induction C-reactive protein levels (CRP), concomitant immunomodulator use, concomitant corticosteroid use, and any requirement for subsequent surgery.
Definitions of response and remission
Response to adalimumab was documented at 6 weeks post-induction, at the time of the fourth injection, the point at which patients were assessed for self-administration of adalimumab. Response was defined by a decrease in HBI of ≥2 points from baseline, with remission defined using an HBI score of ≤ 4, or using a physician's global assessment in those patients where HBI could not be recorded due to the presence of a stoma. Sustained clinical benefit with adalimumab during continuing therapy was defined by continued response to therapy, according to a physician's global assessment, at the last time point of follow-up. Corticosteroid-free sustained clinical benefit was also documented at the last point of followup, but only in those patients who were receiving corticosteroids on commencement of adalimumab. Corticosteroid-sparing effects were defined by any decrease in the total daily corticosteroid dosage, compared with that at the initiation of adalimumab, at the patient's last point of follow-up.
Primary non-response to adalimumab was defined as failure to achieve a decrease in HBI of ≥ 2 at 6 weeks, at the time of the fourth dose of adalimumab. Secondary non-response was defined according to a physician's global assessment of relapse of disease activity during continued treatment, in all patients who had responded to initial adalimumab induction therapy.
Statistical analysis
All categorical data were compared between patients, according to reason for the discontinuation of infliximab, using the Pearson χ Wallis one-way analysis of variance, depending on the number of comparisons made. The proportion of patients experiencing response after 6 weeks of therapy, and sustained clinical benefit at the last point of follow-up was calculated for all individuals, and long term response to adalimumab therapy was assessed using KaplanMeier survival plots. The association between demographic data, lifestyle factors, disease characteristics, previous infliximab regimen used, concomitant medications, and reason for the discontinuation of infliximab and the likelihood of achieving either response or sustained clinical benefit were explored using univariate analysis. All statistical analyses were performed using SPSS for Windows version 14.0 (SPSS Inc, Chicago, Illinois, USA).
Results
A total of 44 patients were treated with adalimumab as second-line anti-TNFα therapy at our centre between 2007 and 2010. Demographic data of all individuals, and according to reason for the discontinuation of infliximab, are provided in Table 1 . The median duration of CD prior to first use of infliximab was 72 months (interquartile range (IQR) , and the median duration of therapy prior to the discontinuation of infliximab was 23.5 months (IQR 2-40.25). On commencement of adalimumab therapy, 21 (47.7%) of the 44 patients were receiving concomitant immunomodulator therapy. Fifteen (71.4%) of these 21 were receiving azathioprine and six were receiving methotrexate. Adalimumab induction therapy was administered as 160 mg at week 0 followed by 80 mg at week 2 and then 40 mg EOW in 22 (50.0%) patients, with the remainder receiving 80 mg at week 0 followed by 40 mg EOW. Median follow-up after commencement of adalimumab in all patients, including those with primary non-response, was 10 months (IQR 6-18.25). Patient characteristics were similar according to reason for the discontinuation of infliximab therapy, with the exception that those who discontinued due to primary non-response had a significantly shorter median duration of infliximab therapy (P b 0.001, Kruskal-Wallis), and there were fewer individuals in the secondary non-response group who had luminal CD only (P = 0.04, Kruskal-Wallis).
Efficacy of adalimumab induction therapy at 6 weeks
Nine (20.5%) patients were classified as primary non-responders to adalimumab, and one patient had adalimumab therapy withdrawn during induction due to an adverse event (a hypersensitivity reaction, similar to that which the patient had experienced with infliximab). Of the nine patients who had primary non-response, five (55.6%) had also been primary non-responders to infliximab therapy. The mean HBI for these patients on commencement of therapy was 14 (range 5-26), compared with 13 (range 4-26) after adalimumab induction. Six had luminal disease and three had both luminal and fistulising disease. The clinical outcomes of the primary nonresponders to adalimumab were surgical intervention in seven (77.8%), recommencement of oral corticosteroids in one, and no further intervention in the remaining patient. Of the patients who underwent surgical intervention all had inflammatory disease rather than fibrostentotic disease, and were therefore classified as true adalimumab failures.
Thirty-four (77.3%) of the 44 patients had a response to adalimumab therapy, as defined by a ≥2 decrease in HBI from baseline, or a physician's global assessment (Fig. 1) . Five of these patients had a stoma. Of the 29 responders where the HBI could be recorded, the mean HBI decreased from 10 prior to the commencement of the therapy, to 4 after adalimumab induction (P b 0.0001). Response rates at 6 weeks according to patient characteristics are provided in Table 2 . These were significantly higher in patients who had discontinued infliximab due to intolerable adverse events, compared with those who experienced primary non-response to infliximab, and there was a trend towards higher response rates in patients with secondary non-response to infliximab compared with primary non-responders. There was also a trend towards those individuals receiving concomitant immunosuppression demonstrating higher response rates. In total, including the primary nonresponders to adalimumab, 19 (48.7%) of the 39 patients where HBI was able to be recorded were in remission at 6 weeks, defined by an HBI score of ≤ 4, after three injections of adalimumab.
CRP levels were recorded at baseline and post induction with adalimumab. The median baseline CRP in the responder group was 8.3 (IQR 5-27.5) and 11.2 (IQR 5-15.5) in the primary non-responder group (P = 0.94). Following induction therapy, the median CRP was 5 (IQR 5-12.95) in the responders, and 32 (IQR 5-59) in the primary non-responders (P = 0.04).
Efficacy of maintenance adalimumab therapy during follow-up
Overall, 28 (63.6%) of 44 patients had a sustained clinical benefit with adalimumab and were still receiving therapy at the last point of follow- 20) . Two of these patients had only 2 months of follow-up postcommencement of adalimumab therapy, but both were in remission, as determined by an HBI of ≤4 after induction therapy at 6 weeks, and neither were on oral corticosteroids at commencement of adalimumab. Four patients who had experienced primary non-response to infliximab had a sustained clinical benefit with adalimumab. None of these patients received a further intervention in the period between the two biological therapies which may have influenced any subsequent response to adalimumab (median time to switch from infliximab to adalimumab was 3 months). The delay in the initiation of adalimumab therapy, following infliximab failure occurred because an approval from the Leeds Primary Care Trust was required, up until 2010, in all cases before the commencement of adalimumab therapy in this situation. Sustained clinical benefit according to patient characteristics is provided in Table 3 , and the proportion of patients with sustained clinical benefit out to 24 months of therapy is reported in Fig. 2 . There was a trend towards higher rates of sustained clinical benefit with an induction regimen of 160 mg followed by 80 mg, but this did not reach statistical significance. However, the median duration of follow up for patients receiving 160 mg/80 mg induction was significantly shorter than for those receiving 80 mg/40 mg induction (8 months versus 18 months, P = 0.003, Mann-Whitney U test). Only one patient switched to receive adalimumab on a weekly basis in order to sustain clinical benefit, and de-escalation of therapy back to EOW was not appropriate in this case due to clinical concerns relating to further relapse of disease. Seventeen (60.7%) of the 28 patients with sustained clinical benefit were on oral corticosteroids at the commencement of adalimumab therapy. Fifteen were receiving prednisolone at a mean dose of 25 mg, and two were receiving budesonide at a dose of 9 mg. Nine (52.9%) of these 17 patients had discontinued all corticosteroids at the last point of follow-up. A further seven patients (41.2%) had a reduction in corticosteroid dose (mean reduction of 13 mg per patient), and one patient remained at the same dose.
Of the remaining six patients who had an initial response to adalimumab induction therapy, but who did not go on to achieve sustained clinical benefit, two required cessation of therapy due to intolerable adverse events, one of whom ultimately required surgical resection. The remaining four developed secondary nonresponse to adalimumab. Two of these patients also had secondary non-response to infliximab, and the other two had discontinued infliximab due to infusion reactions. All four of these patients ultimately required surgical resection. One of these patients had both inflammatory and multifocal fibrostenotic disease, and is being reconsidered for adalimumab following surgery of the fibrostenotic bowel; the other three all had inflammatory disease. None of the patients with secondary non-response to adalimumab had dose escalation of therapy prior to surgery.
Safety of adalimumab therapy
There were nine patients (20.5%) who experienced adverse events with adalimumab therapy, two of whom required cessation of therapy. One of these was a hypersensitivity reaction, which occurred several hours post adalimumab injection with the patient experiencing jaw pain, dizziness and shortness of breath. Interestingly, infliximab was discontinued in this patient for the same reason. The other adverse event requiring cessation of therapy, was a psoriatiform skin rash. Of the remaining seven patients, three reported injection site reactions, two demonstrated diffuse maculopapular skin reactions, and two developed opportunistic infections. Neither of the latter two patients was receiving concomitant immunosuppression. One case was a localised oral infection with Primary non-response = 9
Intolerable adverse event = 1
Secondary non-response = 4
Intolerable adverse events = 2 44 patients discontinuing infliximab therapy and commenced on adalimumab
Response to initial therapy = 34
Sustained clinical response = 28 Figure 1 Flow of study participants.
Herpes simplex, and the other a reactivation of Varicella zoster in the form of shingles in the lumbosacral region. In both cases, temporary suspension of adalimumab therapy was required whilst the patient received a course of oral acyclovir, and adalimumab was successfully reintroduced, although one of these two patients subsequently developed secondary non-response to therapy. There were no malignancies among these 44 patients at the last point of follow-up.
Discussion
This study, conducted in a single tertiary referral centre for IBD in the United Kingdom, demonstrates that adalimumab is efficacious and well-tolerated in CD patients who have failed infliximab therapy previously. Almost 80% of patients failing infliximab therapy for any reason had an initial response to adalimumab, and almost two-thirds went on to experience sustained clinical benefit. Of those who were receiving corticosteroids at baseline, over half achieved corticosteroid-free sustained clinical benefit at the last point of follow-up, with dose reduction of corticosteroids in all but one of the remaining patients. Withdrawal of corticosteroids is a key treatment aim in CD, with data from the TREAT registry implicating concomitant corticosteroid use with biologics as being associated with higher rates of mortality and serious infection. 17 When data were analysed according to the reason for infliximab failure, response rates to induction therapy were significantly higher in individuals who had discontinued infliximab due to intolerable adverse events, and were also higher in secondary non-responders to infliximab, but these effects were not observed for a sustained clinical benefit. There was also a trend towards sustained clinical benefit with adalimumab being more likely in patients receiving a 160 mg/80 mg adalimumab induction regimen although this may be confounded by a shorter median follow-up in this group compared with the patients who received an 80 mg/40 mg induction, and longer-term prospective follow-up may clarify this point. Nearly half of the primary non-responders to infliximab had a sustained clinical benefit with adalimumab, indicating that the primary non-response to a biological agent does not necessarily translate across the class of therapies. In addition, two-thirds of patients who had secondary non-response to infliximab experienced sustained clinical benefit to adalimumab, perhaps suggesting that their continued response to infliximab may have been modified by ATIs, and that the response to anti-TNFα therapy can be recaptured by switching biological therapies. Of note, there were trends towards patients on concomitant immunosuppression being more likely to respond to, and have sustained benefit with, adalimumab therapy (odds ratio 5.07 and 2.93 respectively). This may suggest that concomitant immunosuppression reduces the formation of antibodies to adalimumab, which have been shown to both decrease efficacy and lower serum levels of the drug 18, 19 though, as we did not measure antibodies routinely as part of our study, whether this is the explanation in our patients remains unclear. In addition, a high proportion of patients who discontinued infliximab therapy due to intolerable adverse events responded to adalimumab induction. Tolerability of adalimumab was excellent, with only two patients stopping therapy due to intolerable adverse events, and two documented opportunistic infections that may have been attributable to adalimumab.
Interestingly, smoking status had no effect on the likelihood of initial response or sustained clinical benefit to adalimumab in our cohort, a finding replicated in a similar study of second-line biological use in CD. 20 A recent systematic review that assessed whether smoking status affected response to infliximab therapy suggested that data are conflicting, and found that many studies were limited by the lack of a clear definition of "smoking" itself, in terms of duration of smoking, or pack year history of cigarette usage. 21 The majority of patients who discontinued adalimumab, whatever the reason, required surgery. This highlights the importance of achieving sustained clinical benefit when switching biologics, as these patients tend to have a complex or aggressive disease phenotype where surgery may be the only alternative if such therapies fail. Indeed, nearly half of the patients in our cohort had already had surgical interventions prior to adalimumab therapy, with almost one third of these having had more than one CD-related operation.
Strengths of the study include the follow-up duration of up to 3 years for some patients, with a median duration of follow-up of 15 months among continued responders, its prospective nature, and the fact that it provides the largest single UK centre experience of treating patients with adalimumab as a second-line anti-TNFα therapy to date, demonstrating that switching biologics in CD after failure of first-line therapy is an efficacious and worthwhile strategy. Weaknesses include the fact that it was conducted in a tertiary referral centre, meaning that the participants may not be generalisable to those patients failing infliximab encountered in secondary care. This may also have led to an underestimation of the efficacy of adalimumab as a second-line biologic, as the patients recruited in this study are likely to be more complex, and therefore resistant to conventional medical therapies. Response to therapy was assessed at 6 weeks, when patients began to self-administer the drug. This time point may have been too soon to confidently determine primary non-response to therapy. However, surgery was considered for the majority of these patients, rather than continuation or dose escalation of the drug, if they were symptomatically worse on therapy. Dose escalation is now used routinely in our clinical practise, and this may contribute to achieving or recapturing response in those failing the adalimumab therapy. In addition, HBI scores were only available on institution of therapy and upon assessment of response to induction therapy; they were not used to assess continued efficacy. This was largely due to the fact that patients who responded to adalimumab induction selfadministered subsequent therapy at home, and further clinical assessment, in the IBD clinic, did not include routine documentation of HBI scores. Furthermore, minor adverse events may have been underestimated in this study as patients self-injecting adalimumab could experience side effects that go unreported.
There have been other studies published that examine the use of adalimumab following infliximab failure. The largest, a double-blind RCT, reported the efficacy of induction with adalimumab in infliximab failures, and included 155 patients from 52 centres. 15 Data from this trial demonstrated a 52% response rate after 4 weeks of therapy. Another multicentre study assessing the response to adalimumab induction in infliximab failures demonstrated efficacy in fistulising disease, with complete fistula closure in 23% at 4 weeks, and remission in 42% of patients with luminal disease. 20 However, both of these studies only included patients who had lost response to, or suffered intolerable adverse events with, infliximab thus excluding the important subgroup of primary non-responders, a cohort of patients included in the present study. Other studies, both multicentre and from single centres, have demonstrated efficacy of adalimumab as maintenance therapy with response or remission rates (depending on which was being assessed) at 52 weeks of between 30% and 70%, including the 1-year extension of the GAIN study and the recently published CHOICE trial. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] However, with the exception of a nationwide study from Scotland and the Mayo clinic experience, 22, 31 these studies are limited either by small participant numbers, the exclusion of primary non-responders to infliximab from the dataset or by no recording of remission or response rates. More recently, a retrospective review of 42 patients previously treated with infliximab indicated only a 2% clinical remission rate with subsequent adalimumab therapy, with a minority (19%) achieving corticosteroid tapering. 32 Either discontinuation or dose reduction of corticosteroids was seen in over 80% of our cohort, which is in line with other published studies of similar sizes. 24, 26 Adverse events to adalimumab in patients with previous infliximab intolerance were documented in our cohort, but are Figure 2 Kaplan-Meier survival plot describing proportion of patients with sustained clinical benefit (%) over time (months).
few. Two out of 17 of our cohort who had previously had intolerable adverse events to infliximab ceased adalimumab therapy due to similar reactions. Youdim et al., observed 7 infliximab allergic patients who subsequently received adalimumab. 33 No reactions were seen on adalimumab therapy, with the exception of one patient who had previously received pooled human immunoglobulin, which is worth noting given that adalimumab is a fully humanised antibody. In a Scottish multicentre cohort of 88 patients who had previously received infliximab, two deaths were observed following adalimumab therapy, 22 although we did not observe any in our cohort of patients.
Further work reporting longer term outcomes in patients who have switched biological therapy still needs to be conducted, as do exit strategies for those patients who may wish to stop biological therapy when in sustained remission, but who may need reintroduction of therapy if they experience a flare of disease activity. Concerns regarding the efficacy of such an approach, and worries over lack of therapeutic options if second-line biologics fail, may lead to patients being maintained on therapy long into remission, and therefore longer term efficacy and safety data will help direct the clinician and patient's treatment decisions in the future.
Long-term therapies for CD need to be effective, safe, and tolerable. In this single centre UK study we provide further data to support these attributes with regard to treatment with adalimumab. Adalimumab was efficacious and well-tolerated in patients who had already been exposed to infliximab therapy in both an episodic and scheduled fashion, for both luminal and fistulising disease, and in primary non-responders to infliximab.
